Viela Bio begins clinical trials months after $250M spinoff

Viela Bio begins clinical trials months after $250M spinoff
<span>By: Tim Curtis Daily Record Business Writer August 20, 2018<br>One of Maryland&rsquo;s best-funded biotech companies took a milestone first step Monday, announcing it has begun clinical trials of a medication it is developing. Gaithersburg-based Viela Bio was spun out of MedImmune, a subsidiary of AstraZeneca, last month with $250 million in financing and a...</span>

By: Tim Curtis Daily Record Business Writer August 20, 2018

One of Maryland’s best-funded biotech companies took a milestone first step Monday, announcing it has begun clinical trials of a medication it is developing. Gaithersburg-based Viela Bio was spun out of MedImmune, a subsidiary of AstraZeneca, last month with $250 million in financing and a promise of creating 100 jobs within five years. Monday’s announcement is a first ...

Read Full Publication

Source: thedailyrecord.com